DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2012; 137(49): 2589-2590DOI: 10.1055/s-0032-1327300 Korrespondenz | Correspondence Erwiderung © Georg Thieme Verlag KG Stuttgart · New York Chronisch-obstruktive Lungenerkrankung (COPD) - Erwiderung Chronic obstructive pulmonary disease (COPD) A.-R. Koczulla 1 Klinik für Pneumologie, Universitätsklinikum Gießen – Marburg, Standort Marburg › Author Affiliations Recommend Article Abstract Buy Article Full Text References Literatur 1 Andersson F, Borg S, Jansson SA et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96: 700-708 2 FDA. Follow-up to the october 2008 updated early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). 2010 3 FDA. Early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). 2008 4 Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. JAMA 2008; 300: 1439-1450 5 Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554 6 Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364
